Seventh Sense is focused on developing novel diagnostics applicable to both validated and emerging biomarkers. Our product platform enables the rapid development of diagnostics that can detect several classes of analytes including small molecules, peptides, proteins, and nucleic acids. Our products will offer unprecedented simplicity of use, rapid turn-around time, and lifestyle compatibility. By making regular monitoring or screening practical, this new class of diagnostics could result in dramatically improved health outcomes and reduced healthcare expenditures by allowing earlier disease detection and better patient management, particularly those with chronic disease.
Our proprietary product pipeline is focused on diagnostics for clinical indications with high unmet medical need and large commercial opportunities.